Fighting neurodegenerative disease

with new therapies emerging from ground-breaking research relating to repeat associated non-ATG (RAN) Translation
RanTran is a development stage company whose mission is to investigate, develop and commercialize therapies to fight neurodegenerative disease, one of the cruelest killers of all.
arrow down

Publications, Articles & News

Press Releases

Potential treatment pathway for genetic form of ALS and FTD


Metformin inhibits RAN translation through PKR pathway and mitigates disease in C9orf72 ALS/FTD mice


The identification and manipulation of pathways that block RAN translation or target RAN proteins using gene therapy can be developed as a platform technology to fight C9orf72 ALS/FTD and a large category of other diseases involving RAN proteins.

Scroll to Top